HISTORICAL FACTS: Scott plesha | History Defined

Pelthos Therapeutics Q1 Earnings Call Highlights

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch, executives said on the company’s 2026 first-quarter earnings call. Chief Executive Officer Scott Ples

MarketBeat · May 16

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.

Benzinga · Nov 7, 2025